£6 9-10-61

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this rsons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995

Substitute for form 1449A/PT0

INFORMATION DESCLOSU STATEMENT BY APPLICAN

(use as many sheets as necessary)

11 of 1 Sheet

-	required to respond to a collection of	information unless it contains
Ť	Tedanos sa vas,	Complete if Known
ļ	Number	09/724,288
ŀ	Application Number	November 27, 2000
١	Filing Date	Dale B. Schenk
١	First Named Inventor	1647
	Group Art Unit	Unassigned
	Examiner Name	15270J-004765US
	Attorney Docket Number	152705-0041 000 0
_		

				U.S. PATENT DOCUM	LIVIO	Pages, Columns, Lines,
xaminer	Cite	U.S. Patent Docum Kind Co Number	de²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
HILLIAIS		(II KITOW	<u>'''</u>	Pandolfo et al.	11-21-2000	
50	196	6,150,091		Stamler et al.	05-02-2000	
4-	1	6,057,367		Snow	09-28-1999	
	2	5,958,883		Suzuki et al.	09-21-1999	
-	3	5,955,317		Mond et al.	09-21-1999	
-	4	5,955,079		Hsiao et al.	03-02-1999	
	5	5,877,399		Weiner et al.	02-09-1999	
	6	5,869,093		Weiner et al.	02-09-1999	
	7	5,869,054		Findeis et al.	12-29-1998	
-+-	8	5,854,204		Kline	12-22-1998	
	9	5,851,996		Weiner et al.	12-15-1998	
\dashv	10	5,849,298		Maggio e al.	11-17-1998	
-+-	11	5,837,473		Konig et al.	07-28-1998	
	12	5,786,180		Potter	07-14-1998	
	207	5,780,587		McMichael et al.	05-19-1998	
	13	5,753,624		Suzuki et al.	05-12-1998	
	14	5,750,349		Goldgaber et al.	04-28-1998	
\vdash	197	5,744,368	<u> </u>	Sette et al.	04-07-1998	
┝╌╁╌	211	5,736,142		Weiner et al.	03-31-1998	
	15	5,733,547		Solomon	11-18-1997	
 	16	5,688,651		Nesburn et al.	10-21-1997	
 	17	5,679,348		Hafler et al.	07-08-1997	
 	18	5,645,820			06-24-1997	
1	19	- 244 474		Hafler et al. Hafler et al.	06-24-1997	
1	20	2 244 473			03-18-1997	
}+	21	7.040.400		McConlogue et al. Seubert et al.	02-25-1997	
1	- 22	T 005 011		Mond et al.	12-17-1996	
1-1		5 505 400		Mond et al. Hafler et al.	11-05-1996	
1	2	= === 500			11-05-1996	
1				Hafler et al. Seubert, et al.	08-15-1995	
1		5,441,870			07-18-1995	
1		6 5,434,170		Andrulis, Jr.	02-07-1995	
		7 5,387,742		Cordell	12-14-1993	
 		5,270,165		Van Nostrand et al.	07-27-1993	
 	1	5,231,000		Majocha et al.	06-15-1993	
-		5,220,013	$\neg \top$	Ponte et al.		

29 5,220,013		
Examiner	Date Considered	2-2-02
Signature Signature	onformance with MPEP 6	609. Draw line through citation if not in conformance

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any Duruen nour Statement: This form is estimated to take 2.0 nours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents Washington, DC 20231. Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is place a check mark here if English Japanese Translation is attached. to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use diffugin 10/31/2002. OMB 0631-3031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
of 1500 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Pape Substitute for form 1449APTOSEP 1 0 2001

INFORMATION DISCLOS STATEMENT BY

(use as many sheets as necessary)

Complete if Known 09/724,288 Application Number November 27, 2000 Filing Date Dale B. Schenk First Named Inventor 1647 Group Art Unit Unassigned Examiner Name 15270J-004765US Attorney Docket Number

Sheet	2	of 11			
			Eppstein et al.	05-04-1993	
95	30	5,208,036	McGeer et al.	03-09-1993	
1-9-	31	5,192,753	Cordell et al.	02-16-93	
	32	5,187,153	Kensil et al.	10-15-1991	
 	33	5,057,540	Pardridge	04-0201991	
 - - 	198	5,004,697	Glenner et al.	05-19-1987	
40	34	4,666,829	Gleffiler et al.		
-/30					

			gn Patent Docum		PATENT DOCU	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner	Cite No.1	Office ³	. 4 Kin	d Code ⁵	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
Initials*	NO.	Office		A2		04-28-1999		
CRI	35	EP	911 036	A2 A2		10-07-1998		늗=
1	36	EP	868 918	A1		09-09-1998		-
	37	EP	863 211	A1		06-03-1998		
	38	EP	845 270	A1		07-09-1997		1 - 1
_	39	EP	782 859	A1		11-22-1995		
	40	EP	683 234	A1		08-09-1995		
	41	EP	666 080	B1		12-16-1998		十
-+-	42	EP	652 962	B1		11-03-1999		+
-+-	43	EP	639 081	A2		08-31-1994		十
	44	EP	613 007	B1		08-27-1997		十吉
	45	EP	594 607			08-04-1999		十吉
	46	EP	561 087	B1		05-28-1997		十号
	47	EP	526 511	B1		03-15-2000		十
	48	EP	506 785	B1		10-16-1991		十吉
	49	EP	451 700	A1	 	01-24-1996		十吉
	50	EP	440 619	B1 B1		11-29-1995		1 🗟
	51	EP	359 783	B1		12-08-1993		十音
 	52	EP	276 723			07-09-1997		十吉
 	187	EP	783 104	A1 A1		12-21-2000		十 岩
	199	PCT	00/77178			07-27-2000		
H-1-	188	PCT	00/43049	A1		11-25-1999		ᆛᆣ
-	53	PCT	99/60024	A1		11-15-1999		
	54	PCT	99/60021	A2		11-18-1999		
-	55	PCT	99/58564	A1		02-11-1999		
	56	PCT	99/06066	A2		06-10-1999		╌┼╌╞
 	57	PCT	99/27949	A1		06-10-1999		
lah	58	PCT	99/27944	A1		1	_	

7 0 ** **		
Examiner	Date Considered	12-2-02
Signature	formance with MPEP 6	609. Draw line through citation if not in conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside #

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ersons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paper Substitute for form 1449A/P

INFORMATION STEE STATEMENT BY APP

(use as many sheets as necessary)

11 3

required to recept	Complete if Known
Application Number	09/724,288
	November 27, 2000
Filing Date	Dale B. Schenk
First Named Inventor	1647
Group Art Unit	Unassigned
Examiner Name	15270J-004765US
Attorney Docket Number	

	3	l of	11		Altorney Docker Telling	
Sheet	3				20.40.4000	
	T	PCT	99/27911	A1	06-10-1999	
36	59	PCT	99/00150	A2	01-07-1999	
<u> </u>	203	PCT	98/44955	A1	10-15-1998	
	60	PCT	98/07850	A2	02-26-1998	
	61		97/21728	A1	06-19-1997	
	202	PCT	97/17613	A1	05-15-1997	
	62	PCT	96/39176	A1	12-12-1996	
	63	PCT	96/28471	A1	09-19-1996	
	208	PCT	96/25435	A1	08-22-1996	
	64	PCT	96/18900	A1	06-20-1996	
	65	PCT	95/31996	A1	11-30-1995	
	66	PCT	95/12815	A1	05-11-1995	
	200	PCT	95/12813		05-04-1995	
\neg	67	PCT		A1	04-27-1995	
	68	PCT	95/11311	A1	03-02-1995	
	69	PCT	95/05853	A2	02-09-1995	
	70	PCT	95/04151	A1	12-08-1994	
	201	PCT	94/28412	A1	02-17-1994	
	71	PCT	94/03615	A1	01-20-1994	
	72	PCT	94/01772	A1	11-11-1993	-
	73	PCT	93/21950	A1	09-02-1993	-
	74	PCT	93/16724	A1	08-19-1993	
	75	PCT	93/15760	A1	07-22-1993	
	76	PCT	93/14200	A1	03-04-1993	
	205	PCT	93/04194	A1	02-04-1993	
	77	PCT	93/02189	A1	08-06-1992	——————————————————————————————————————
	78	PCT	92/13069	1 A1	04-30-1992	
	79	PCT	92/06708		04-16-1992	
	80	PCT	92/06187	A1	12-26-1991	
	81	PCT	91/19810	A1	11-14-1991	
	82	PCT	91/16819	A1	09-05-1991	
	83	PCT	91/12816	A1	06-27-1991	
1	84	PCT	91/08760	A1	11-01-1990	
-	85	PCT	90/12871	A1	11-01-1990	+
\vdash	86	PCT	90/12870	A1	02-23-1989	
	87	PCT	89/01343	A1	07-13-1989	
1-1-	88	PCT	89/06242	A1	07-27-1989	
H	89	PCT	89/06689	A1	05-05-1989	
1	90	PCT		A1	12-29-1988	
10	91	PCT	88/10120	A1		

91 PCI 90.000		
Examiner	Date Considered	12-2-02
Signature	farmance with MPEP	609. Draw line through citation if not in conformance

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Coffice, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents Washington, DC 20231. Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00) Please type a plus sign (+) inside this

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paper Substitute for form 1449A/PTO SEP

INFORMATION DISCLOSES STATEMENT BY APPRICANT

(use as many sheets as necessary)

of

Complete if Known 09/724,288 Application Number November 27, 2000 Filing Date Dale B. Schenk First Named Inventor 1647 Group Art Unit Unassigned **Examiner Name** 15270J-004765US Attorney Docket Number

Sheet 4	of 11	Autoritey beautorities	4.4000
92 93	GB 2 220 211 GB 2 335 192	A 1	4-1990 5-1999

Date Examiner Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is placed a check mark here if English Japanese Translation is attached.

PTO/SB/08	8	, 1	(0	8	-00))
				_		

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995 papersons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PT	SEP	ן ט צטטו	GE T
INFORMATION STATEMENT B	VAL YA	CLOS!	NT

Complete if Known 09/724,288 **Application Number** November 27, 2000 Filing Date Dale B. Schenk First Named Inventor 1647 Group Art Unit Unassigned **Examiner Name** 15270J-004765US Attorney Docket Number

(use as many sheets as necessary) 11 of 5 Sheet

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or T² Cite Examiner ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," Neurology. Nο Initials 94 Associated Press, "Immune cells may promote Alzehimer's, a study finds," The Boston Globe (4/13/95). 95 BAUER et al., "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," FEBS Letters, 285(1):111-114 (1991). 96 BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice,* Eur. J. Immunol. 29:345-354 (1999). 204 BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheomer's Diseases," Soc. for Neuroscience Abstracts 18:764 (1992). 212 BARD et al., *Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nature Medicine, 6(8):916-919 (2000). 176 BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," New England J. Medicine, 341(22):1694 (1999). 97 BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease, "Biochem. Biophys. Res. Comm., 171(2):890-897 (1990). 98 BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," Neuron, 19: 939-945 (1997). 99 BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," Cur. Opin. Genet Develop., 3: 102-109 100 BRICE et al., "Absense of the amyloid precursor protein gene mutation (APP717 : Val->lle) in 85 cases of early onset Alzheimer's disease, J. Neurology, Neurosurg, Psychiatry, 56:112-115 (1993). 101 CHAO et al., "Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury," Soc. Neurosci. Abstracts, 19:513.7 (1993). 102 CHEN et al. *An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," Neuroscience Letters 125:223-226 (1991). 213 DEMATTOS et al., "Peripheral Anti Aβ Antibody Alters CNS And Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mouse Model of Alzheimer's Disease," Proc. Natl. Acad. Sci. USA, 10.1073/pnas.151261398 (2001). 214 DUFF et al., "Mouse model made," Nature, 373: 476-477 (1995). 103

Examiner Signature	Date Considered	109 Draw line through citation if not in conformance

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark comments on the amount of time you are required to complete this form should be sent to the Chief minormation Chicer, U.S. Fatent and Traderio Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Chief. Washington, DC 20231. Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Office: U.S. DEPARTMENT OF COMMERCE

Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

OFFICE: U.S. D Under the Paperwork B

Substitute for form 1449A/PTO

SEP 1 0 2001

INFORMATION DESCLOSU STATEMENT BY ARTHUR

(use as many sheets as necessary) of 11

required to respond to a collection of	Information unless it contains			
Complete if Known				
	09/724,288			
Application Number	November 27, 2000			
Filing Date	Dale B. Schenk			
First Named Inventor	1647			
Group Art Unit	Unassigned			
Examiner Name	15270J-004765US			
Attorney Docket Number	152703-00476300			

		of	l 11	Attorney Docket Human	_	
heet	6			this Darkinson's disease," J. Neurol.	5 I	
~	104	ELIZAN et	al., "Antineurofilament antibo	odies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol.</u> <u>Sciences</u> , 59:341-347 (1983).		
P-		FEI SENST	Sciences, 35.5474 ELSENSTEIN et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," Neuroscience Letters, 152:185-189 (1993).			
\bot	105		Tecomonic	a wheid and Inflammatory Features of Alzheimer Disease,"		
	106	FINCE	Neuro	obiology of Aging, 17(5):809-815 (1996). obiology of Aging, 17(5):809-815 (1996). oid precursor protein gene in mouse oocytes and embryos," PNAS, 88:1779- 1782 (1991).	0	
	107	FISHER et	al., "Expression of the amylo	1782 (1991).		
	108	FLANDERS	S et al., "Altered expression of	of transforming growth factor-β in Alzheimer's disease," Neurology, 45:1561-1569 (1995).		
-	210	FRIEDLA	ND et al., ""Development of Alzheimer	an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in r's disease," Mol. Neurology, 9:107-113 (1994).		
	109	GAMES	et al. "Alzheimer-type neur	ropathology in transgenic mice overexpressing V/17F p-arrivoid property (1995).		
		CAMES	et al. "Prevention and Reduc	ction of AD-type Pathology in PDAPP Mice Immunized with Aβ ₁₋₄₂ ," Annals of Annals of April of Science 920:274-84 (2000).		
	215	0,	the New	zheimer's disease: some possible therapeutic opportunities," <u>TiPS</u> , 13:108-113 (1992).		
	110	GANDY 6	(al., Allylologe	es reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.,</u> 177:1181-1186 (1993).		
	111	GAS	KIN et al., "Human antibodic	177:1181-1186 (1993).		
	112		GLENN et al., "Skin immu	unization made possible by cholera toxin," Nature, 391: 851 (1998).		
 	113	GL	_ENNER et al., "Alzheimer's /ascular Amyloid Protein," <u>Bi</u>	Disease: Initial Report of the Purification and Characterization of a Novel iochemical and Biophysical Research Communications, 120(3): 885-890 (1994).	 	
	114	CLENN	FR et al., "Alzheimer's Disea	ase and Downs Syndrome: Sharing of A Sharing	+-	
	 	GOATE	et al "Segregation of a mi	issense mutation in the amyloid precursor protein government and says 704-706 (1991).	+	
	115	GOZES et al., "Neuroprotective strategy for Alzheimer PNAS, 93:		rategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," PNAS, 93:427-432 (1996).	1	
	116			PNAS, 93:427-432 (1995). PNAS, 93:427-432 (1995). PNAS, 93:427-432 (1995).	1	
	190 GRAVINA et al., "Amyloid β Protein (Aβ) in Alzheimer's Diseas		AVINA et al., "Amyloid β Pro	otein (Aβ) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995). e immunogenicity of native and formalized cross reacting material (CRM197) of pigs and their implications on the development and control of diphtheria vaccine pigs and their implications of the development.		
	11	GUF dipthe	PTA et al., "Differences in the eria toxin in mice and guinea basec	e immunogenicity of native and formalized cross reacting material (CRMT67) of pigs and their implications on the development and control of diphtheria vaccine of the organization of the development of the organization of the o	+	
<u> </u>	+	НУС		d on CRMs," <u>Vaccine, 15(12/13). 1541-15-15</u> Her amyloid β/A4 peptides enhance production of complement C3 component by discreption of the discr		

Examiner Signature	Date Considered	09. Draw line through citation if not in conformance
. u tion in	La conformance with its C. C.	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this bo

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ersons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995.

Substitute for form 1449A/PT

INFORMATION DESCLOSI STATEMENT BY APPURANT

(use as many sheets as necessary)

required to respond to a consistence	Complete if Known
Application Number	09/724,288
	November 27, 2000
Filing Date	Dale B. Schenk
First Named Inventor	1647
Group Art Unit	Unassigned
Examiner Name	15270J-004765US
Attorney Docket Number	102700-001700

		of 111 Attorney booker values
Sheet	7	
56	119	HANES et al., "New advances in microsphere-based single-dose vaccines," Advanced Drug Delivery Reviews, 28: 97-119 (1997).
7	120	HARDY, "Amyloid, the presentlins and Alzheimer's disease," TINS, 20(4): 154-159 (1997).
-+	-	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," Annals of Med., 28:255-258 (1996).
\perp	121	A PRINCTON et al. "Characterisation of an epitope specific particle corresponding to the C-terminus of β / A4-
/	193	recognised by a monoclonia cretein " Biochimica Biophysica Acta, 1156: 120-120 (1665)
	177	HELMUTH, L., "Further Progress on a β-Amyloid Vaccine," Science, 289:375 (2000).
	122	HSIAO et al., "Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice," Science, 274: 99-102 (1996).
	123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," J. Neuroimmunology, 52:147-152 (1994).
	123	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," N. E. J. Medicine, 333(19):1283-1284 (1995).
	124	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease, grant in ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease, grant in ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease, grant in ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease, grant in ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease, grant in ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease, grant in ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease, grant in ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease, grant in ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease, grant in ITAGAKI et al., "Relationship of microglia and astrocytes
	125	
	192	IWATSUBO et al., "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-opening of Aβ42(43)," Neuron, 13:45-53 (1994). Evidence That an Initially Deposited Species Is Aβ42(43)," Neuron, 13:45-53 (1994).
	126	IANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Gylden Government (1982).
		JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," Am. J. of Pathology 138:373-378 (1991).
	216	des associated with the acute-phase response in Alzheimer's
	127	Lastibodies in preventing carboxypeptidase A aggregation,
	18	the stranggeric mice
-	12	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature, 354:476-478 (1991).
	19	KONIG et al., "Development and Characterization of a Monoclonal Antibody 333.25 (1996).
-	+	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 microscopic and C4
	1	Frontal Cortex During Alzheimer's Discosor, Salzen Science, 249: 1527-1532 (1990). LANGER, "New Methods of Drug Delivery," Science, 249: 1527-1532 (1990).
5	6 1) LANGER, "New Methods of Drug Delivery," 3333

Examiner	Date Considered	12-2-02
Signature	s in conformance with MPEP 6	09. Draw line through citation if not in conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PΊ	0/	SB	/08	3,4	•	(0	8-()0)	Ì
					_				ď

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ersons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork R

Substitute for form 1449A/PTO

INFORMATION DISC STATEMENT BY

(use as many sheets as necessary)

Sheet

e required to respond to a collection of	(Michiladori di Ressi il santa			
Complete if Known				
i dan Number	09/724,288			
Application Number	November 27, 2000			
Filing Date	Dale B. Schenk			
First Named Inventor				
Group Art Unit	1647			
Examiner Name	Unassigned			
Attorney Docket Number	15270J-004765US			
Attorney Docker Training				

			_ ı	
6	131	LANNEELT et al., "Alzheimer's disease: molecular genetics and transgenic arillina models,"	믜	
7	132	- I- Dd Ann Transgenic		
	132	tia Hymons by Linoneptide Vaccination		
	133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by 2-popular Action of the Comparable to Those Elicited by Acute Viral Infection," J. Immunol., 159: 1383-1392 (1997). LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," Acta. Neurol. Scand., 84:441-444 (1991).		
,	134	out 1.4 amulaid in Alzheimer's Disease Brain for		
	218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimov (1992). Application to In Vitro Imaging of Amyloid Angiopathy," The J. of Nuclear Med. 33:2184-2189 (1992).	금	
	217	Application to in Vitro imaging of Arrysectory MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," Proc. Natl. Acad. Sci. USA, 82:4245-4249 (1985).		
	135	MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro. Encap.</u> , 14(2): 197-210 (1997).		
	136	NEDA et al. "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995).		
		MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991).		
	137	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J. Biol. Chem.,		
	206	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994).		
	191	Immunohistochemical Readitify		
	138	Chine,		
	139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94). PARESCE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," Neuron, 17:553-565 (September 1996).		
	140	PARESCE et al., "Microglial cells influence aggregates of the Azaromic 1996). scavenger receptor," Neuron, 17:553-565 (September 1996).		
	141	PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," <u>Eur. J.</u> Immunol., 25: 3521-3524 (1995).	-	
-	142	PRIEELS et al., "Synergistic adjuvants for vaccines," Chemical Abstracts, 120(8): pg. 652, column 1, abstract 864061 (1994).		
1	143	QUON et al., "Formation of β-Amyloid protein deposits in brains of transgenic mice," Nature, 352:239-241 (1991).	_ _	
100		PASO V.A. Grant application.#1=R43.AGI-5746-01-(publication/date unknown)		
	144	11 VIO		

Examiner	21	Date Considered	12-2-02
Signature	Delle	MDED	609. Draw line through citation if not in conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Aug

Substitute for form 1449A/PTO

SEP 1 0 2001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known		
Application Number	09/724,288	
Filing Date	November 27, 2000	
	Dale B. Schenk	
First Named Inventor	1647	
Group Art Unit	Unassigned	
Examiner Name	15270J-004765US	
Attorney Docket Number	152703-00470300	

		of 11 Attorney Docket Number
Sheet	9	
	145	RASO, "Immunotherapy of Alzheimer's Disease," Immunotherapy Weekly, Abstract (April 2, 1998).
9	146	ROGERS et al., "Complement activation by β-amyloid in Alzheimer Disease," PNAS, 89:1-5 (1992).
	147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," Annals of New York Academy of Sciences, 695:198-202 (1993).
		RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in Peptide Hormones, J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).
	209	Hormonies, J.A. Faisch, et al. Recolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243
	189	SAIDO et al., "Spatial Resolution of a California (1993). (1993).
	194	SAIDO et al., "Spatial Resolution of the Primary β-Amylolougenic 7 100005 in
	178	SCHENK et al., "Therapeutic Approaches Related to Amyloid-β Peptide and Alzheimer's Disease," J. Med. Chem., 38(21):4141-4154 (1995).
		SCHENK et al., "Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 400:173-177 (1999).
	148	SELKOE, D.J., "Imaging Alzheimer's Amyloid," Nat. Biotech., 18:823-824 (2000).
	149	
	150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," J. Neuropathol, Exp. Neurol., 53(5): 438-447 (1994).
	151	SELKOE, "Physiological production of the β-amyloid protein and the medianism of Alexander Neurosciences, 16(10): 403–409 (1993).
	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease," Scientific American, pgs. 68-78 1991).	
		SELKOE, Dennis J., "In the Beginning," Nature, 354:432-433 (1991).
	153	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," Neuron, 6:487-498 (1991).
1	154	
	155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).
1	156	SELIBERT et al., "Isolation and quantification of soluble Alzheimers p-periode from Bloogless."
-	157 SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-255 (1992).	
1-4		SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997).
	D 158	SMITS et al., "Priori Protein and Gordpo George

Examiner	Date Considered	12-2-02
Signature	MDED	609 Draw line through citation if not in conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Dersons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Red

Substitute	for form	1449A/PT

SEP 1 0 2001 2

INFORMATION DISCLOSE STATEMENT BY

(use as many sheets as necessary)

Complete if Known				
Application Number 09/724,288				
	November 27, 2000			
Filing Date	Dale B. Schenk			
First Named Inventor	1647			
Group Art Unit	Unassigned			
Examiner Name	15270J-004765US			
Attorney Docket Number 152703-00470000				

Sheet 10 Sol.OMON et al., "Nonoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide,"		000 00		7 -6	11		Attorney Docket Number	
SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide," PNAS, 93.452-455 (1996) SOLOMON, A., "Pro-Rx (Protein-Therapeuses)," "University of Tennesseartherical Genter (publication descriptions) PNAS, 93.452-455 (1996) TO SOLOMON, B., "New Approach Towards Fast Induction of Znatip β-amyloid peptide degree and the state of Molecular Microbiology," Biotechnology," Et Alvy University of Tennesseartherical Genter (publication date of Molecular Microbiology, Biotechnology," Et Alvy University of Tennesseartherical Genter (publication date of Molecular Microbiology, Biotechnology," Et Alvy University (Parimar Auvy-Tela-Arvy), Etal-publication date of Molecular Microbiology, Biotechnology," Etal-Arvy University (Parimar Auvy-Tela-Arvy), Etal-publication date of Molecular Microbiology, Biotechnology, Etal-Arvy University, Etal-Publication of Carboxypeptidase A by Conjugation with Polyviny Parimar Microbiology and Solomos, Adv. Mol. Cell Biology, 16A:39-35 (1996) Parimar Solomos, 16A:39-35 (1996)	Sheet	10		of				_
SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibriliar aggregation of the Abbeiterior Power Power Protein Therapetics," "Chikipsisiy of Tennessee Medical-Genter-(publicatipn-date-unknown)." "Chikipsisiy of Tennessee Medical-Genter-(publication-date-unknown)." "Chikipsisiy of Tennessee Medical-Genter-(publication-date-unknown)." "Chikipsisiy of Tennessee Medical-Genter-(publication-date-unknown)." "Chikipsisiy of Tennessee Medical-Genter-(publication-date-unknown)." "Chikipsisiy of Medical-date-unknown)." "Chik			Τ-				f Alzheimer ß-amyloid by site-directed mAb," PNAS, 94:4109-4112 (1997).	븨
SOLOMON, A., "Pro-Rx (Prolain-Therapspülics)," University of Tennesseer Medical-genter-publical production of Amption of Marking Amption of Period Information of Amption of Amption of Amption of Period Information of Amption of Amption of Period Information of Amption of Period Information of Amption of Period Information of Information of Amption of Amption of Period Information of Information I	96	159		OLOMO	N et al., "I	Disaggregation of	odies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide,"	
SOLOMON; B., "New Apphasch Towards Fast Induction of Anti p: Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, "El-Xivi University: Ramar Aviv, "El-Aviv) Faraer-(publication.date-water Aviv) (Paramy Stranger Aviv) (Paramy Stranger) (Paramy Stra	26	160	S	OLOMOI	N et al., "	WONOCIONAL CAMP	PNAS, 93:452-455 (1996). Stherengelitics). "University of Tennessee Medical Center (publication date	
SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β-amyloid peptide aggregation," Int. J. SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," Biochem. Mol. Biol. Int., 43(3)801-611 (1997). SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," Adv. Mol. Cell Biology, 15A:33-45 (1996). SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," Adv. Mol. Cell Biology, 15A:33-45 (1996). SOLOMON et al., "Ackinity of monoclonal antibodies in-prevention-of-in, vitro aggregation-of-their antigenes," abstract from Department of Molecular Microbiology and Biotechnology, 21et Aviv-University, 21et Aviv-Liversity, 21et Aviv-Liv		161	_	SOLOMON, A., "Pro-Rx" (Prof			unknown). In Profest Town Community (Peptide Immune Response," Department Peptide Immune Response, Department Peptide Immune Response, Department Peptide Immune Response (Peptide Immune Response).	
SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. May. Biol. Int.</u> , 43(3):801-811 (1997). SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyviny! Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996). SOLOMON et al., "Activity of microclonal-antibodies: in-prevention-oi-in-witro-aggregation-of-in-like antigenes," abstract from Department of Molecular Microbiology and Biotechnology, Etal Aviv-University. <u>15A Javi-Jarseal (pyblication_date_lomn_pay.</u> <u>In Dioty 11 (1996).</u> SOUTHWICK et al., "Assessment of Amyloid p protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1996). STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malaria", <u>N. Engl. J. Med.</u> , 336(2): 86-91 (1997). STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 34: 13287-13292 (1997). TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352-135-142 (1998). TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen," <u>Proteins Corporations of Mayloid-Protein in cerebrospinal fluid increase with age in patients free from 1916 (2-3):114-115 Abstract C.37, (1994). VAN GOOL et al., "Concentrations of amyloid-Protein in cerebrospinal fluid increase with age in patients free from 2016 (2-3):14-115 Abstract C.37, (1994). WERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Journ. Pathology</u>, 144(1):104-116 (1994). WEINER et al., "CORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-180 (1997). WEINER et al., "Bovine spongiform enephalogopathy and early onset var</u>		162	S S	OLOMON of Mole	r B., "Nev cular Micr	obiology & Biotec	chnology, Tel-Aviv University, Ramar Aviv. uaknown).	
SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyviny Alcohols," Adv. Mol. Cell Biology, 15A.33.45 (1996). SOLOMON et al., "Activity of monoclonal-antibodies-in-prevention-of-in-vitro aggregation-of-their-antigens,"-abstract from Department of Molecular Microbiology and Biotechnology, Tel. Aviv. University, Tel. Apriv. Espace (pithbication, date, mon. Department of Molecular Microbiology and Biotechnology, Tel. Aviv. University, Tel. Apriv. Espace (pithbication, date, mon. Department of Molecular Microbiology and Biotechnology, Tel. Aviv. University, Tel. Apriv. Espace (pithbication, date, mon. Department of Molecular Microbiology and Biotechnology, Tel. Aviv. University, Tel. Apriv. Espace (pithbication, date, mon. Department of Molecular Microbiology, and Biotechnology, Tel. Aviv. University, Ed. 259-265 (1996). SOUTHWICK et al., "Assessment of Amyloid proteory for protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease." Neurochemistry, 66:259-265 (1996). STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoile Protein Vaccine Against Plasmodium Falciparum Malaria", N. Engl., J. Med., 338(2): 88-91 (1997). STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology." PNAS, 94: 13287-13292 (1997). TANAKA et al., "N.C1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology, 352:135-142 (1998). TRIEB et al., "N.C1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology, 352:135-142 (1998). TRIEB et al., "N.C1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology, 352:135-142 (1998). TRIEB et al., "N.C1900, an active fragment analog of ar	56	182	1 8	OLOMO	N et al., "I	nhibitory effect of	of monoclonal antibodies of Azatamor p Exp. Clin. Invest., 3:130-133 (1996). A see Expection of PH and Ionic Milieu," <u>Biochem. Mol.</u>	님
SOLOMON et al., "Activity of monoclonal-antibodies in-prevention of in-intro aggregation to the from Department of Molecular Microbiology and Biotechnology. Tel. Aviv. University, "Tel. AyrivIsrael (publication date, inform Department of Molecular Microbiology and Biotechnology. Tel. AvivUniversity, "Tel. AyrivIsrael (publication date, inform Department of Molecular Microbiology and Biotechnology. Tel. AvivUniversity, "Tel. AyrivIsrael (publication date, inform Department of Molecular Microbiology and Biotechnology. Tel. AvivIsrael (publication date, inform Department of Molecular Microbiology and Biotechnology. Tel. AvivIsrael (publication date, inform Department of Molecular Microbiology). Tel. AvivIsrael (publication date, inform Department of Molecular Microbiology). Tel. AvivIsrael (publication date, inform Department of American Department Protein Vaccine Against Plasmodium Department Plasmodium Department Plasmodium Department Protein Protein Protein Protein Protein (1997). 164 STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. PNAS, 94: 13287-13292 (1997). 165 TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of induced by beta-amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of 191(2-3):114-115 Abstract C.37, (1994). 166 TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of 191(2-3):114-115 Abstract C.37, (1994). 167 VAN GOOL et al., "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neuroscience Letters. 172:122-124 (1994). 168 VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Neuroscience Letters.	50	184	S	OLOMON	l et al., "T		A by Conjugation with Polyviny	님
179 SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," J. Neurochemistry, 66:259-265 (1996). 179 STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against Plasmodium Palciparum Melaria", N. Engl. J. Med., 336(2): 86-91 (1997). 163 STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," PNAS, 94: 13287-13292 (1997). 164 STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," PNAS, 94: 13287-13292 (1997). 165 TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology, 352:135-142 (1998). 166 TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology, 191(2-3):114-115 Abstract C.37, (1994). 167 VAN GOOL et al., "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neuroscience Letters, 172:122-124 (1994). 168 VERBEEK et al., "Accumulation of intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994). 169 WALKER et al., "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994). 180 WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantilgens," Annu. Rev. Immunol., 12:809-837 (1994).	8	185	5	SOLO	MON et al	, "Modulation of Alcoh	The Catalytic Pathway of Carboxypeptates hols, "Adv. Mol. Cell Biology, 15A.33-45 (1996). hols, "Adv. Mol. Cell Biology, 15A.33-45 (1996). clonal antibodies in-prevention of in-vitro aggregation-of-their antigens; "abstract clonal antibodies in-prevention of law in-vitro aggregation-of-their antigens; "abstract clonal antibodies in-prevention of law in-vitro aggregation-of-their antigens; "abstract clonal antibodies in-prevention of law in-vitro aggregation-of-their antigens; "abstract clonal antibodies in-prevention of law in-vitro aggregation-of-their antigens; "abstract clonal antibodies in-prevention of law in-vitro aggregation-of-their antigens; "abstract clonal antibodies in-prevention of law in-vitro aggregation-of-their antigens; "abstract clonal antibodies in-prevention of law in-vitro aggregation-of-their antigens; "abstract clonal antibodies in-prevention of law in-vitro aggregation-of-their antibodies in-prevention of law in-vitro aggregation-of-their antibodies in-prevention of law in-vitro aggregation-of-their antibodies in-prevention of law in-vitro aggregation of law in-vitro aggregatio	0
STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against Plasmodium Falciparum Malaria", N. Engl. J. Med., 336(2): 86-91 (1997). STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," PNAS, 94: 13287-13292 (1997). TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology. 352:135-142 (1998). TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology. 191(2-3):114-115 Abstract C.37, (1994). VAN GOOL et al., "Concentrations of amyloid-# protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neuroscience Letters, 172:122-124 (1994). VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994). WALKER et al., "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994). WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994).		18	6	rom Dep	artment o		uaknowy: 17 19 19 19 19 19 19 19 19 19 19 19 19 19	
STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-inc pathology," PNAS, 94: 13287-13292 (1997). 165 TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology. 352:135-142 (1998). 166 TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology, 191(2-3):114-115 Abstract C.37, (1994). 167 VAN GOOL et al., "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neuroscience Letters, 172:122-124 (1994). 168 VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994). 169 WALKER et al., "Labeling of Cerebral Amyloid In Vivo with a Monocional Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994). 180 WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994).	56	17	9	SOL	JTHWICK	Alzhomi	Protein Vaccine Against Plasmodium	
TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology. 352:135-142 (1998). TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology. 191(2-3):114-115 Abstract C.37, (1994). 167 VAN GOOL et al., "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neuroscience Letters. 172:122-124 (1994). 168 VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994). 169 WALKER et al., "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994). 180 WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994).		16	33	STOUTE	et al., "A	Preliminary Evali Falcipar	transgenic mouse models with Alzheimer disease-like	
TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides coresponding of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology, 191(2-3):114-115 Abstract C.37, (1994). 167 VAN GOOL et al., "Concentrations of amyloid-\$\theta\$ protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neuroscience Letters, 172:122-124 (1994). 168 VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994). 169 WALKER et al., "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994). 180 WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994). WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," Curr.		1	64	STURCH			Learning and memory delicits	
166 the APP sequence states 191(2-3):114-115 Abstract 0.01 (1914). 167 VAN GOOL et al., "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neuroscience Letters, 172:122-124 (1994). 168 VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994). 169 WALKER et al., "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody," J. Neuropath. Exp. Neurology. 53(4):377-383 (1994). 180 WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994). 180 WEINER et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," Curr. Orac Neuropipil. 7:695-700 (1997).		1	65	TANAKA	et al., "N induc	C-1900, an active ced by beta-amylo	to tragment analog of expressions. Pharmacology, 352:135-142 (1995); loid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1995); loid protein in rats, " <u>European J. Pharmacology</u> , 352:135-142 (1995); long protein in rats, " <u>European J. Pharmacology</u> , 352:135-142 (1995); long protein in rats, " <u>Immunobiology</u> , with Alzheimer's disease," <u>Immunobiology</u> ,	
VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Joum. Pathology, 144(1):104-116 (1994). WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," J. Neuropath. Exp. Neurology. 53(4):377-383 (1994). WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994). WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994).			166	the APP	sequenc	- Junior	191(2-3):114-115 Abstract 0.07, (1917)	
WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurology.</u> 53(4):377-383 (1994). WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-837 (1994). WEINER et al., "Bovine Spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <u>Curr.</u> Orio Neuropiol. 7: 695-700 (1997).			167	VAN G	OOL et a	1104.02.0	Plagues in Brain Tissue of patients	
WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organian WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organian Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994). WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organia Communication of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994).			168	VERE	SEEK et a	I., "Accumulation with Alzheime	of Intercentual Admission Pathology, 144(1):104-116 (1994). er's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994). Little Vivo with a Monoclonal Antibody," J. Neuropath. Exp. Neurology,	[
Specific Autoimmune Discosses, Curr. Specific Autoimmune Discosses, Curr. Land Specific Autoimmune Discoss			169					
WEISSMANN et al., "Bovine spongiform encephatopathy and a service of the			180	WE Spec	INER et a	al., "ORAL TOLEI nmune Diseases	by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-037 (100-1)	<u>.</u> [
	9	5	170	WEI	SSMANN	et al., "Bovine sp	Opin, Neurobiol., 7: 695-700 (1997).	

80 110		
Examiner Signature	Date Considered	09. Draw line through citation if not in conformance
Signature	is a conformance with MPEP o	Ug. Diaw into anosa

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE on are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Re Substitute for form 1449A/PTO

INFORMATION DISC STATEMENT BY AFRICA

(use as many sheets as necessary)

Complete if Known 09/724,288 **Application Number** November 27, 2000 **Filing Date** Dale B. Schenk First Named Inventor 1647 Group Art Unit Unassigned **Examiner Name** 15270J-004765US Attorney Docket Number

She	et	11	of 11	
			WEN, G.Y., "Alzheimer's Disease and Risk Factors," <u>J. Food Drug Analysis</u> , 6(2):465-476 (1998).	
8	6	171	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," Nature Biotech., 18:868-824 (2000).	
	 	172	A Carebray oscular Amyloid in Alzheimer Disease are Antigenically Related," Proc.	
	1_	219	this processing and AR42 deposition in a transgenic mouse model of Alzheimer	
8	\$	173		0
_	γ	174	THuman-Immunology & Cancer Program-brochure-from The University of Tenessee Medicar Center/ Graduate-School of Medicine-Knoxville,⊸Fennessee (publication-date-unknown). ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑	DC.

Examiner	Slaves	Date Considered	12-2-02
Signature	Camp		and the state of the conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to Complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to Complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the Amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent on the Chief Inform Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.